New treatment options for lymphoma patients, that does not require chemotherapy Wednesday, September 26, 2018 The results of the CCTG LY.16 trial of Rituxmab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE), recently published in New England Journal of Medicine, has the potential to offer a new treatment option to lymphoma patients, that does not require chemotherapy. Find out more.
